BIOMAT Database Logo BIOMAT Database Logo

A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) 1991

N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Memorial Sloan-Kettering Cancer Center, New York, New York.

OBJECTIVE To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer. METHODS Retrospective analysis. METHODS Regional cancer treatment center. METHODS Forty-four previously untreated patients with metastatic colorectal cancer in a phase I-II trial of PALA-fluorouracil. RESULTS One or more transient hepatic abnormalities frequently occurred in 15 of the 17 responding patients. Within the first 10 weeks of treatment, 5 patients developed ascites, 12 had a decrease in the serum albumin level, 6 developed bilirubin elevations, and 7 had transaminase elevations, all in the presence of a complete or partial tumor response. Prolongations of the prothrombin time and elevations of serum glucose levels were also seen. CONCLUSIONS An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen. These abnormalities, which may be related to decreased hepatic protein synthesis, occurred more often in patients whose tumor was responding to chemotherapy. Clinicians must recognize that in patients undergoing chemotherapy with these agents, ascites and elevated liver function tests may be secondary to drug administration and are not necessarily due to disease progression.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D010746 Phosphonoacetic Acid A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. Phosphonoacetate,Disodium Phosphonoacetate,Fosfonet Sodium,Phosphonacetic Acid,Phosphonoacetate, Disodium
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006932 Hyperbilirubinemia A condition characterized by an abnormal increase of BILIRUBIN in the blood, which may result in JAUNDICE. Bilirubin, a breakdown product of HEME, is normally excreted in the BILE or further catabolized before excretion in the urine. Bilirubinemia,Bilirubinemias,Hyperbilirubinemias
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000637 Transaminases A subclass of enzymes of the transferase class that catalyze the transfer of an amino group from a donor (generally an amino acid) to an acceptor (generally a 2-keto acid). Most of these enzymes are pyridoxyl phosphate proteins. (Dorland, 28th ed) EC 2.6.1. Aminotransferase,Aminotransferases,Transaminase

Related Publications

N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
N-(Phosphonacetyl)-L-aspartate (PALA): current status.
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
January 1982, Molecular pharmacology,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
September 1997, Annals of oncology : official journal of the European Society for Medical Oncology,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
July 1992, Annals of internal medicine,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
January 1979, Cancer chemotherapy and pharmacology,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
June 1983, Cancer research,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
November 1981, European journal of cancer & clinical oncology,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
October 1993, Pharmaceutical research,
N Kemeny, and K Seiter, and D Martin, and C Urmacher, and D Niedzwiecki, and R C Kurtz, and P Costa, and M Murray
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
January 1996, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!